Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

157.53 -1.91 (-1.20%)
Streaming Delayed Price Updated: 12:48 PM EDT, Jun 9, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S ADR

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Up 463%, This Sizzling Growth Stock Could Have a Lot More Room to Run
Viking Therapeutics stock might in the midst of a historic run. 
Via The Motley Fool
Should You Buy Viking Therapeutics Stock After It Skyrocketed Over 60%?
Viking could have a strong rival to Novo Nordisk's Wegovy and Ozempic and Lilly's Mounjaro in the making. 
Via The Motley Fool
Viking Therapeutics' Initial VK2735 'Data Resoundingly Beat Expectations,' Analyst Says
Earlier today, Viking Therapeutics Inc (NASDAQ: VKTX) announced the first-in-human single-ascending dose and multiple-ascending dose data of VK2735. 
Via Benzinga
Is Viking Therapeutics a Smart Buy on the Dip?
The stock recently fell around 25% for reasons that had nothing to do with its lead program. 
Via The Motley Fool
The Ozempic Obesity Battle Is Heating Up With Novo Scoring A Fresh Win
The company is working on an oral version of its cult-following injection, Ozempic. 
Via Investor's Business Daily
Looking Into Novo Nordisk's Recent Short Interest
 
Via Benzinga
Novo Nordisk Suspended From UK Trade Association For Practice Breaches
 
Via Benzinga
Here's How Much You Would Have Made Owning Novo Nordisk Stock In The Last 5 Years
 
Via Benzinga
If You Invested $100 In This Stock 5 Years Ago, You Would Have $300 Today
 
Via Benzinga
Novo Nordisk's Higher Dose Oral Semaglutide Shows Superior Reductions In Sugar Levels, Body Weight
 
Via Benzinga
Chart Of The Day: Novo Nordisk - All Time High
Revenue is expected to grow 17.80% this year and another 13.50% next year. Earnings are estimated to increase by 32.70% this year and an additional 10.90% next year. 
Via Talk Markets
2 Top Healthcare Stocks to Buy for the Long Haul
Both companies have outperformed the market over the past year. 
Via The Motley Fool
Three Is Company - Sanofi Follows Lilly, Novo Nordisk, Slashes Insulin Product Price By 78%
 
Via Benzinga
Novo Nordisk Follows Eli Lilly In Slashing Insulin Prices By 75%
 
Via Benzinga
Best-Selling Drugs by Bristol Myers, Pfizer, AbbVie Likely Candidates For US Price Negotiation
 
Via Benzinga
Novo Nordisk: Impulsive Sequence Favors Upside & Remain Supported
Novo Nordisk A/S, a healthcare company engages in the research, development, manufacture and marketing of the pharmaceutical products worldwide. 
Via Talk Markets
Jimmy Kimmel Jokes At Oscars About Hollywood Stars Using This Diabetes Drug To Lose Weight — Roasts Will Smith Slap Too
During the 95th Academy Awards ceremony hosted by Jimmy Kimmel on Sunday night, he poked fun at the rumor that Hollywood actors are using Ozempic, Novo Nordisk’s (NYSE: NVO) diabetes drug, to lose... 
Via Benzinga
BRTX’s ThermoStem®: A New Weapon In The Fight Against Metabolic Syndrome
By Julian Richard, Benzinga 
Via TheNewswire.com
BRTX’s ThermoStem®: A New Weapon In The Fight Against Metabolic Syndrome
BRTX’s ThermoStem®: A New Weapon In The Fight Against Metabolic Syndrome 
Via News Direct
BRTX's ThermoStem®: A New Weapon In The Fight Against Metabolic Syndrome
Metabolism is the chemical process whereby the body produces energy from food. By breaking down carbohydrates and fats into sugars, the cells access fuel that can be used or stored via the liver or... 
Via Benzinga
Looking To Shed Some Pounds? WeightWatchers To Offer Weight-Loss Drugs Like Ozempic
WW International Inc (NASDAQ: WW), formerly known as “WeightWatchers” announced Monday in its earnings call that the company is acquiring Sequence, a telehealth company that can 
Via Benzinga
WW Stock Soars As Telehealth Deal Opens Up Hot Obesity Drug Market
Former WeightWatchers is entering clinical weight management. WW stock surged. 
Via Investor's Business Daily
AI Stock Headlines 5 Leaders Flashing Buy Signals As Market Rally Gains Steam
Arista Networks leads this watch list of stocks near buy points. 
Via Investor's Business Daily
Eli Lilly Slashes Insulin Prices By 70%, Will Other Insulin Makers Follow Suit?
Eli Lilly & Co (NYSE: LLY), in an effort to make it easier for patients to access affordable insulin and navigate the complex healthcare system, announced on Wednesday a 70% reduction in the list price... 
Via Benzinga
Analysts Sees Over 50% Upside Opportunity For This Newly Listed Obesity Player Stock, Participating In Big Pharma Race
 
Via Benzinga
Novo Nordisk: Big Gains In Diabetes And Obesity Care
Danish pharmaceutical giant Novo Nordisk released its fourth quarter results, reporting $7.1 billion in revenues, up 22% year-over-year compared to $5.8 billion a year ago. With its diabetes and... 
Via Talk Markets
With COVID-19 Having Placed A Sharp Focus On Syringes, This Innovator Looks Back At A Year Of Successes Since Their 2022 IPO
Medical device company Sharps Technology Inc. (NASDAQ: STSS) is taking stock as it approaches one year since its initial public offering (IPO). Since its IPO, the company has taken major strides in... 
Via Benzinga
2 Market-Beating Growth Stocks That Are Just Getting Started
Winners keep winning. 
Via The Motley Fool
BioRestorative Therapies Inc (NASDAQ: BRTX) Announces European Patentability Of ThermoStem® Program With Indications In Obesity And Type 2 Diabetes
By Julian Richard, Benzinga 
Via TheNewswire.com
Topics Intellectual Property
Exposures Intellectual Property
BioRestorative Therapies Inc (NASDAQ: BRTX) Announces European Patentability Of ThermoStem® Program With Indications In Obesity And Type 2 Diabetes
BioRestorative Therapies (NASDAQ: BRTX), a clinical-stage biotechnology company focused on stem cell-based therapies, announced on the 8th of February that the European Patent Office had issued a... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.